A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Mark T.J. van Bussel
  • Ahmad Awada
  • Maja J.A. de Jonge
  • Morten Mau-Sørensen
  • Dorte Nielsen
  • Patrick Schöffski
  • Henk M.W. Verheul
  • Barbara Sarholz
  • Karin Berghoff
  • Samer El Bawab
  • Mirjam Kuipers
  • Lars Damstrup
  • Ivan Diaz-Padilla
  • Jan H.M. Schellens

Background: This open-label, phase 1 trial (NCT02316197) aimed to determine the maximum-tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of peposertib (formerly M3814), a DNA-dependent protein kinase (DNA-PK) inhibitor in patients with advanced solid tumours. Secondary/exploratory objectives included safety/tolerability, pharmacokinetic/pharmacodynamic profiles and clinical activity. Methods: Adult patients with advanced solid tumours received peposertib 100–200 mg once daily or 150–400 mg twice daily (BID) in 21-day cycles. Results: Thirty-one patients were included (median age 66 years, 61% male). One dose-limiting toxicity, consisting of mainly gastrointestinal, non-serious adverse events (AEs) and long recovery duration, was reported at 300 mg BID. The most common peposertib-related AEs were nausea, vomiting, fatigue and pyrexia. The most common peposertib-related Grade 3 AEs were maculopapular rash and nausea. Peposertib was quickly absorbed systemically (median Tmax 1.1–2.5 h). The p-DNA-PK/t-DNA-PK ratio decreased consistently in peripheral blood mononuclear cells 3–6 h after doses ≥100 mg. The best overall response was stable disease (12 patients), lasting for ≥12 weeks in seven patients. Conclusions: Peposertib was well-tolerated and demonstrated modest efficacy in unselected tumours. The MTD was not reached; the RP2D was declared as 400 mg BID. Further studies, mainly with peposertib/chemo-radiation, are ongoing. Clinical trial registration: NCT02316197.

OriginalsprogEngelsk
TidsskriftBritish Journal of Cancer
Vol/bind124
Udgave nummer4
Sider (fra-til)728-735
Antal sider8
ISSN0007-0920
DOI
StatusUdgivet - 16 feb. 2021

Bibliografisk note

Publisher Copyright:
© 2020, The Author(s).

ID: 286306026